NCT04514289

Brief Summary

to assess and compare the performance two approaches for sentinel lymph node ( SLND) biopsy

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
106

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2020

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

July 29, 2020

Completed
16 days until next milestone

First Posted

Study publicly available on registry

August 14, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2021

Completed
Last Updated

August 14, 2020

Status Verified

August 1, 2020

Enrollment Period

1.3 years

First QC Date

July 29, 2020

Last Update Submit

August 13, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • SLN detecting rate

    SLN is the first lymph node to spread tumoral cells.

    1 year

Secondary Outcomes (2)

  • Overall survival

    5 years

  • Disease free survival

    5 years

Study Arms (2)

assesment SLND with enjection by using ICG

Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The first group in which the cervix is injected superficially with 1 mL of ICG ( indocyanine green) at 4 and 8 o'clock quadrans.

Drug: Indocyanine green solution

assesment SLND with hysterescopy by using ICG

Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The second one which ICG has injected the uterine cavity during hysteroscopy. Our aim is to assess and compare the performance two approaches for sentinel lymph node ( SLND) biopsy.

Drug: Indocyanine green solution

Interventions

Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.

Also known as: No indocyanine green solution
assesment SLND with enjection by using ICGassesment SLND with hysterescopy by using ICG

Eligibility Criteria

Age18 Years - 90 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients who have experienced endometrial cancer surgery

You may qualify if:

  • The patient must be willing and able to provide informed consent
  • The patient is willing and able to comply with the study protocol
  • The patient has endometrial cancer and is performed SLND
  • The patient agrees to follow-up examination out to 5-years post-treatment

You may not qualify if:

  • The patient is not a candidate for surgery
  • The patient has metastasis
  • The patient has known or suspected allergies to iodine, indocyanine green( ICG)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cihan Comba

Istanbul, Sultangazi, 34265, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Endometrial Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Cihan Comba, M.D.

    Sultangazi Haseki Training and Research Hospital

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
gynecological oncology specialist

Study Record Dates

First Submitted

July 29, 2020

First Posted

August 14, 2020

Study Start

March 1, 2020

Primary Completion

June 30, 2021

Study Completion

August 30, 2021

Last Updated

August 14, 2020

Record last verified: 2020-08

Locations